Mystic Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mystic Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$638K	Sell	1,284 -716	-36%	-$317K	0.14%	125
2026 Q1	$893K	Hold	2,000	–	–	0.21%	105
2025 Q4	$907K	Hold	2,000	–	–	0.21%	99
2025 Q3	$783K	Hold	2,000	–	–	0.18%	111
2025 Q2	$890K	Hold	2,000	–	–	0.22%	100
2025 Q1	$970K	Buy	+2,000	New	+$932K	0.26%	94

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mystic Asset Management's VRTX Position: Q2 2026 in Review

Mystic Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 36% in Q2 2026, selling an estimated $317K and leaving 1,284 shares worth $638K. The position accounts for 0.14% of the portfolio, ranked #125.

Mystic Asset Management first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $970K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mystic Asset Management held 1,284 shares of Vertex Pharmaceuticals worth $638K as of Q2 2026.
Mystic Asset Management sold 716 Vertex Pharmaceuticals shares in Q2 2026, an estimated $317K.
Vertex Pharmaceuticals made up 0.14% of Mystic Asset Management's portfolio in Q2 2026, its #125 holding.
Mystic Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Mystic Asset Management's Vertex Pharmaceuticals position peaked at $970K in Q1 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mystic Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.